# Cilostazol 50 mg Tablets Under Fasting Conditions

> **NCT00839930** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cilostazol 50 mg Tablets
- **DRUG:** Pletal®

## Key facts

- **NCT ID:** NCT00839930
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839930, "Cilostazol 50 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00839930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*